[Personalized Treatment for Colorectal Carcinomas].

Area of Science:

• Oncology
• Molecular Pathology
• Surgical Oncology

Background:

• Colorectal carcinoma (CRC) is a leading cause of cancer mortality in Western nations, with a low 5-year survival rate (~15%) for metastatic CRC (mCRC).
• Treatment strategies for CRC are complex and depend on tumor stage, primary tumor location, and metastatic spread.
• Multidisciplinary tumor boards are crucial for optimizing patient treatment plans.

Purpose of the Study:

• To review current and emerging strategies for personalized treatment of colorectal carcinoma.
• To highlight the importance of molecular markers and tumor characteristics in tailoring therapy.
• To emphasize the role of multidisciplinary teams in CRC management.

Main Methods:

• Review of current clinical guidelines and ongoing phase-III trials in CRC treatment.
• Analysis of the impact of molecular biomarkers (e.g., RAS, BRAF, MSI, CDX2, PIK3) on treatment selection.
• Discussion of the role of primary tumor location in treatment decisions for RAS-wild-type mCRC.

Main Results:

• Individualized treatment approaches are essential for both adjuvant and metastatic CRC.
• CDX2-expression, MSI-status, and PIK3-status aid in adjuvant treatment decisions for UICC-stage II patients.
• RAS and BRAF mutational analyses are critical for selecting first-line therapy in metastatic CRC.

Conclusions:

• Personalized medicine is increasingly important in CRC management, moving beyond traditional staging.
• Molecular profiling and tumor location are key determinants for optimal therapeutic strategies.
• Continued research and clinical trials are vital for advancing personalized CRC treatment.